Vasomotor symptom characteristics: are they risk factors for incident diabetes?

Gray, Kristen E.; Katon, Jodie G.; LeBlanc, Erin S.; Woods, Nancy Fúgate; Bastian, Lori A.; Reiber, Gayle E.; Weitlauf, Julie C.; Nelson, Karin M.; LaCroix, Andrea Z.

doi:10.1097/gme.0000000000001033

Cited by 39 publications

(17 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“… 116 , 117 In the Women’s Health Initiative (WHI) observational study, women with severe symptoms of hot flushes and night sweats had a 48% higher risk of incident diabetes at follow-up. 118 They also have evidence of impaired endothelial function and increased subclinical atherosclerosis compared to women without vasomotor symptoms. 119–121 …”

Section: Vasomotor Symptoms and Cardiovascular Disease Riskmentioning

confidence: 99%

Cardiovascular health after menopause transition, pregnancy disorders, and other gynaecologic conditions: a consensus document from European cardiologists, gynaecologists, and endocrinologists

Maas

Rosano

Cífková

et al. 2021

European Heart Journal

199

128

View full text Add to dashboard Cite

Women undergo important changes in sex hormones throughout their lifetime that can impact cardiovascular disease risk. Whereas the traditional cardiovascular risk factors dominate in older age, there are several female-specific risk factors and inflammatory risk variables that influence a woman’s risk at younger and middle age. Hypertensive pregnancy disorders and gestational diabetes are associated with a higher risk in younger women. Menopause transition has an additional adverse effect to ageing that may demand specific attention to ensure optimal cardiovascular risk profile and quality of life. In this position paper, we provide an update of gynaecological and obstetric conditions that interact with cardiovascular risk in women. Practice points for clinical use are given according to the latest standards from various related disciplines (Figure 1).

show abstract

Section: Vasomotor Symptoms and Cardiovascular Disease Riskmentioning

confidence: 99%

Cardiovascular health after menopause transition, pregnancy disorders, and other gynaecologic conditions: a consensus document from European cardiologists, gynaecologists, and endocrinologists

Maas

Rosano

Cífková

et al. 2021

European Heart Journal

199

128

View full text Add to dashboard Cite

show abstract

“…According to a previous study that prospectively examined the association between VMS and incident diabetes among 150,007 postmenopausal Women's Health Initiative participants from 1993 to 2014, VMS was associated with an 18% increase in diabetes risk (95% confidence interval, 1.14–1.22), while VMS severity was similarly associated with the risk of diabetes [ 28 ]. Of note, these associations remained following adjustment for obesity and were more pronounced in women reporting night sweats together with hot flashes than for those reporting hot flashes only [ 28 ]. An association between VMS and insulin resistance, a precursor of diabetes, was also reported by several epidemiologic studies [ 10 29 ].…”

Section: Vms and Dmmentioning

confidence: 99%

Vasomotor Symptoms: More Than Temporary Menopausal Symptoms

Ryu

Park

et al. 2020

J Menopausal Med

View full text Add to dashboard Cite

Vasomotor symptoms (VMS), such as hot flashes and night sweating, are classic menopausal symptoms experienced by a majority of perimenopausal and postmenopausal women. VMS have received a great deal of attention due to their relationship with cardiometabolic risk. Further, accumulating evidence indicates that VMS are associated with an increased risk of several chronic diseases, including metabolic syndrome, type 2 diabetes mellitus, nonalcoholic fatty liver diseases, and osteoporosis in perimenopausal and postmenopausal women. These findings suggest VMS as biomarkers of impaired cardiometabolic conditions rather than just temporary symptoms in menopausal women, warranting further studies to confirm the casual relationship of VMS with these diseases and the exact underlying mechanism in this context.

show abstract

“…Recently, such symptoms have been associated with increased risk of incident T2DM. A total of 150,007 women from the WHI study were prospectively examined for the potential association of T2DM with climacteric symptoms [48]. Interestingly, any vasomotor symptom was associated with an 18% increase in the risk of T2DM [hazard ratio (HR): 1.18, 95% CI 1.14-1.22] and this was independent of obesity.…”

Section: Mht In Women With T2dmmentioning

confidence: 99%

Type 2 Diabetes Mellitus and Menopausal Hormone Therapy: An Update

Paschou

Παπάνας

2019

Diabetes Ther

View full text Add to dashboard Cite

During menopausal transition, various phenotypical and metabolic changes occur, affecting body weight, adipose tissue distribution and energy expenditure as well as insulin secretion and sensitivity. Taken together, these can predispose women to the development of type 2 diabetes mellitus (T2DM). Many women in midlife experience climacteric symptoms, including hot flashes and night sweats. Menopausal hormone therapy (MHT) is then indicated. MHT has a favourable effect on glucose homeostasis in both women without and with T2DM. T2DM was considered in the past as a cardiovascular disease (CVD) equivalent, which would suggest that women with T2DM should not receive MHT. This notion may still deter many clinicians from prescribing MHT to these patients. However, nowadays there is strong evidence to support an individualised approach after careful evaluation of CVD risk. In older women with T2DM (> 60 years old or > 10 years in menopause), MHT should not be initiated, because it may destabilise mature atherosclerotic plaques, resulting in thrombotic episodes. In obese women with T2DM or in women with moderate CVD risk, transdermal 17β-oestradiol could be used. This route of delivery presents beneficial effects regarding triglyceride concentrations and coagulation factors. In peri- or recently post-menopausal diabetic women with low risk for CVD, oral oestrogens can be used, since they exhibit stronger beneficial effects on glucose and lipid profiles. In any case, a progestogen with neutral effects on glucose metabolism should be used, such as natural progesterone, dydrogesterone or transdermal norethisterone. The goal is to maximise benefits and minimise adverse effects.

show abstract

Vasomotor symptom characteristics: are they risk factors for incident diabetes?

Cited by 39 publications

References 48 publications

Cardiovascular health after menopause transition, pregnancy disorders, and other gynaecologic conditions: a consensus document from European cardiologists, gynaecologists, and endocrinologists

Cardiovascular health after menopause transition, pregnancy disorders, and other gynaecologic conditions: a consensus document from European cardiologists, gynaecologists, and endocrinologists

Vasomotor Symptoms: More Than Temporary Menopausal Symptoms

Type 2 Diabetes Mellitus and Menopausal Hormone Therapy: An Update

Contact Info

Product

Resources

About